TROP2-CD89

TROP2-CD89 is an experimental mRNA-based immunotherapy developed by Myeloid Therapeutics. It consists of a lipid nanoparticle (LNP) encapsulating mRNA that encodes a chimeric antigen receptor (CAR) fusion protein. This fusion protein combines an anti-TROP2 single-chain variable fragment (scFv) with the alpha chain of the human IgA receptor (CD89). Upon intravenous administration, the LNPs are taken up by myeloid cells, which then express the TROP2-CD89 receptor. The receptor utilizes the endogenous common Fc receptor gamma chain (FcRγ) to signal and activate the myeloid cells, programming them to recognize and eliminate TROP2-overexpressing cancer cells. Preclinical studies have demonstrated anti-tumor efficacy in models of hepatocellular carcinoma and triple-negative breast cancer.

Other names

anti-TROP2-CD89 fusion proteinanti-TROP-2-CD89 fusion proteinanti-TROP 2-CD89 fusion proteinTROP2-CD89 LNPTROP-2-CD89 LNPTROP 2-CD89 LNP